Podcast
MSL Talk: Tom Caravela
All About Thought Leader Liaison
Summary
This weeks guest is Jim Hahn, Senior Business Director, Thought Leader Engagement at EMD Serono who discusses the role of the Thought Leader Liaison and how it fits into the pharma world.
Key Points
- Thought leader liaisons (TLLs) focus on building deep, strategic relationships with key opinion leaders (KOLs) to align commercial objectives with the needs of healthcare providers.
- TLLs typically come from successful sales backgrounds and do not require advanced scientific degrees, but must have strong interpersonal skills and a thorough understanding of their therapeutic area.
- Effective communication between TLLs, MSLs, and sales reps is crucial to ensure seamless interactions with healthcare professionals and to avoid conflicts over access and time.
This weeks guest is Jim Hahn, Senior Business Director, Thought Leader Engagement at EMD Serono who discusses the role of the Thought Leader Liaison and how it fits into the pharma world.
Thought Leader Engagement, Pharma Industry, Key Opinion Leaders, Strategic Relationships, Healthcare Professionals
Related Topics
You May Also Like
MSL Talk: Tom Caravela
Podcast
MSL Talk: Tom Caravela
How Should Medical Affairs Engage on Social Media
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO